{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:35:14Z","timestamp":1780936514786,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.012","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:15:47Z","timestamp":1749770147000},"page":"423-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Maneesh","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2025.04.012_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41571-022-00655-9","article-title":"The oligometastatic spectrum in the era of improved detection and modern systemic therapy","volume":"19","author":"Katipally","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0003","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0004","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.euros.2021.02.008","article-title":"Oligorecurrent prostate cancer and stereotactic body radiotherapy: where are we now? A systematic review and meta-analysis of prospective studies","volume":"27","author":"Marvaso","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0007","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: A systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0008","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0009","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"New Eng J Med"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2022.04.015","article-title":"Beyond the visible spectrum: considering the oligometastatic hypothesis in the light of a new era","volume":"114","author":"Turchan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0011","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0012","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0013","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0014","article-title":"Advancements in prostate cancer radiotherapy: the role of PSMA PET imaging","author":"Lester-Coll","year":"2025","journal-title":"Practic Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0015","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.3390\/cancers14143302","article-title":"Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer","volume":"14","author":"Galgano","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0016","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"New Eng J Med"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0018","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"New Eng J Med"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0019","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0020","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0021","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0022","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive Prostate cancer: A STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0023","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.annonc.2023.04.515","article-title":"Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer","volume":"34","author":"Sutera","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2016.10.044","article-title":"A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer","volume":"102","author":"O\u2019Shaughnessy","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-022-01662-7","article-title":"Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer","volume":"39","author":"Reyes","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0026","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","article-title":"Systemic and tumor-directed therapy for oligometastatic prostate cancer: the SOLAR phase 2 trial in de novo oligometastatic prostate cancer","volume":"86","author":"Nickols","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ijrobp.2022.06.085","article-title":"Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation and External Beam Radiation","volume":"114","author":"Hao","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II\u20142020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0029","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2019.07.009","article-title":"Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: A multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy","volume":"76","author":"De Bleser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: A prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0031","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter Phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0032","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.euo.2023.09.007","article-title":"PEACE V\u2014Salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): acute toxicity of a randomized phase 2 trial","volume":"7","author":"Ost","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0033","series-title":"ESTRO 2024- abstract book: radiotherapy and oncology volume 194 supplement 1","article-title":"Salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM)","author":"Ost","year":"2024"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0034","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","article-title":"Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought","volume":"78","author":"Bravi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2018.10.041","article-title":"Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review","volume":"76","author":"Ploussard","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0036","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0037","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.euo.2024.03.010","article-title":"Multi-institutional analysis of metastasis-directed therapy with or without androgen deprivation therapy in oligometastatic castration-sensitive prostate cancer","volume":"7","author":"Deek","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0038","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0039","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with Enzalutamide or Placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0040","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"New Eng J Med"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0041","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): primary endpoint results from a phase 2 clinical trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0042","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2025.43.5_suppl.160","article-title":"PERSIAN trial: early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer","volume":"43","author":"Francolini","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0043","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1186\/s12885-022-10374-0","article-title":"SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?","volume":"22","author":"Rans","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0044","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-24-3027","article-title":"PSMA+ extracellular vesicles are a biomarker for SABR in oligorecurrent prostate cancer: analysis from the STOMP-like and ORIOLE trial cohorts","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0045","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2967\/jnumed.117.202945","article-title":"Impact of 68Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0046","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.2967\/jnumed.121.262120","article-title":"PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease","volume":"62","author":"Barbato","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0047","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ijrobp.2024.06.033","article-title":"Ablative radiation therapy to restrain everything safely treatable (ARREST): A phase 1 study of stereotactic Ablative radiation therapy for polymetastatic disease","volume":"120","author":"Nguyen","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0048","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: A randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0049","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.clon.2024.06.047","article-title":"Stereotactic body radiotherapy for oligoprogression in castration-resistant prostate cancer: early toxicity analysis of the TRAP trial","volume":"36","author":"Patel","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.semradonc.2025.04.012_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2025.43.5_suppl.15","article-title":"World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): an analysis from the X-MET collaboration","volume":"43","author":"Tang","year":"2025","journal-title":"JCO"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:05:59Z","timestamp":1750791959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000402"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.012","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Debate 3: Metastasis Directed Therapy in Oligometastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}